Business Context and Reporting Period
This Form 8-K was filed by Amedica Corporation (not Sintx Technologies, Inc.) on April 2, 2015. The report details a material definitive agreement entered into on the same date with MG Partners II, Ltd., an affiliate of Magna Group.
Key Financial Metrics and Debt Structure
The filing focuses on the restructuring of existing debt instruments rather than reporting operational financial metrics such as revenue or cash flow.
- Debt Restructuring: The Company exchanged existing senior convertible notes (aggregate principal of $6,400,000) and an existing warrant for new "Exchange Convertible Notes."
- Specific Note Amounts: The exchange involved notes with principal amounts of $797,649.54 (issued June 30, 2014) and $3,500,000 (issued August 12, 2014).
- Conversion Price: The new notes have an initial conversion price of $1.00 per share, subject to adjustment mechanisms.
- Maturity Date: The notes mature on June 30, 2016, with a potential extension to June 30, 2017, contingent on satisfying certain equity conditions.
- Liquidity and Margins: The filing text does not provide clear values for revenue, profit, operating margins, or general liquidity positions.
Material Changes Versus Prior Period
The primary material change is the cancellation of the original Securities Purchase Agreement dated June 30, 2014, and the issuance of new debt instruments with modified terms:
- Trading Volume Restrictions: The trading price threshold at which volume restrictions on the Investor cease to apply was reset from $2.50 to $0.50.
- Conversion Mechanics: New provisions include an "Alternate Conversion" feature allowing conversion at 80% of the lowest daily VWAP (subject to a $0.20 floor) and "Make-Whole" provisions to compensate the investor if shares are resold below the conversion price.
- Legal Status: The transaction includes a mutual release of claims between the Company and the Investor.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the terms of the debt agreement.
- Unusual Items: The transaction relies on the Section 3(a)(9) exemption from registration under the Securities Act of 1933.
- Contingencies: The maturity date extension to 2017 is contingent upon the Company satisfying specific equity conditions described in the note.
Investor Verification Checklist
- Verify the exact terms of the "equity conditions" required to extend the note maturity to June 30, 2017.
- Review the full text of the Amendment and Exchange Agreement (Exhibit 10.1) for details on the "Make-Whole" calculation and potential dilution.
- Confirm the current trading volume restrictions and the impact of the $0.50 price reset on the Investor's ability to sell shares.
- Check subsequent filings for any updates on the Company's ability to meet the equity conditions for the maturity extension.